US Patent 9,044,475: Sublingual Apomorphine Film Scope, Claims, and Landscape
What does US 9,044,475 claim in plain patent terms?
US 9,044,475 claims a non-effervescent sublingual unit-dosage film or strip with a defined two-layer architecture: an apomorphine acid addition salt particle-containing first layer plus a second layer pH-neutralizing organic base that is paired with a permeation enhancer. The composition is further narrowed through specific excipient classes (mucoadhesive polymers), salt identity, particle-size windows, optional antioxidants, and dosage-range embodiments.
The claim set you provided can be mapped into four gating design constraints and multiple dependent-limiters.
What are the core independent-claim gates (Claim 1)?
Claim 1 defines the product and formulation architecture:
-
Dosage form
- Unit dosage form for sublingual administration
- Film or strip
- Two layers:
- First layer: apomorphine particles comprising an acid addition salt of apomorphine
- Second layer: pH-neutralizing agent that is an organic base
-
Product behavior constraint
-
Transport constraint
- Includes a permeation enhancer (present within the unit dosage form, not limited to which layer in the claim text you supplied)
Litigation/FTS relevance: In infringement analysis, Claim 1 is the highest-value anchor because it requires all of: (i) sublingual film/strip, (ii) two-layer structure, (iii) apomorphine acid addition salt particles in layer 1, (iv) organic-base pH neutralization in layer 2, (v) non-effervescence, and (vi) permeation enhancer.
How do the dependent claims narrow scope (Claims 2-16)?
Below are the most operational dependent-limiters based on your text.
Layer material and polymer selection
- Claim 2: film/strip comprises a polysaccharide.
- Claim 3: mucoadhesive polymer is one of:
- carboxymethylcellulose
- cellulose acetate
- ethylcellulose
- hydroxyethylcellulose
- hydroxypropylmethylcellulose
This is a typical mucoadhesion/material-range narrowing: it reduces design-around space for competitors who pick different film formers (e.g., PVP/VA, pullulan, HPMC only partly overlapping, etc.) while still allowing the listed polymer set.
Salt identity and particle engineering
- Claim 4: acid addition salt is apomorphine hydrochloride.
- Claim 7: effective apomorphine-particle size 1 µm to 10 µm.
- Claim 8: salt is apomorphine hydrochloride (again).
Unit dose amounts (narrow numeric windows)
- Claim 9: 2 to 40 mg acid addition salt per unit dosage form.
- Claim 12: 12 to 30 mg.
- Claim 13-16: specific embodiments for 12 ± 3 mg, 22 ± 4 mg, 30 ± 5 mg, 35 ± 5 mg.
Form-factor and multilayer expansion
- Claim 11: a third layer positioned between the first and second layers (i.e., a branched multilayer architecture variant). This matters for infringement where a product has 3 layers but still keeps layer 1 and layer 2 attributes.
Optional stability/compatibility excipient
- Claim 5: further comprising an antioxidant.
Permeation enhancer specificity (key design-around lever)
- Claim 6: permeation enhancer is glycerol monostearate.
This is the single most direct excipient lock in the set you provided: if a competitor uses another enhancer, they may avoid the precise limiter depending on claim construction and whether “permeation enhancer” in Claim 1 is read broadly or narrowed by Claim 6 in its dependent chain.
What is the practical “claim map” for designing around or positioning products?
From the claim text provided, the formulation space is constrained along these axes:
A. Dosage form architecture
- Sublingual unit film/strip is required.
- Two-layer is required by Claim 1.
- Three-layer is allowed as an embodiment (Claim 11) provided positioning keeps first layer and second layer relationship.
Design-around note: Switching to a different solid sublingual format (tablet, wafer without a layered definition, hydrogel patch, spray) typically attacks the “film or strip” requirement.
B. API form and particle characteristics
- Apomorphine acid addition salt particles in layer 1 are required (Claim 1).
- Salt can be generalized in Claim 1 but is fixed to apomorphine hydrochloride in dependent claims (Claim 4/8).
- Particle size window 1-10 µm appears in Claim 7 (dependent).
Positioning note: If a product uses a different apomorphine salt (not hydrochloride), Claim 1 can still be implicated unless the salt identity is treated as a dependent-only limiter.
C. pH neutralization mechanism
- Layer 2 requires a pH-neutralizing agent that is an organic base.
Design-around note: Replacing the organic base with an inorganic base, using buffering without “neutralizing,” or shifting the neutralization role to another excipient may create literal-scope issues, depending on how “pH neutralizing” is construed.
D. Non-effervescence requirement
- Unit dosage form is not effervescent.
Design-around note: Many sublingual technologies rely on carbonate/citric acid gas generation. Here, that entire pathway is excluded if it is found to be effervescent.
E. Permeation enhancement
- Claim 1 requires a permeation enhancer.
- Claim 6 specifies glycerol monostearate.
Design-around note: Using a different permeation enhancer may reduce exposure to dependent Claim 6 while still implicating Claim 1 if the enhancer qualifies generally as a “permeation enhancer.”
F. Mucoadhesive polymer selection
- Specific polymer exemplars are listed in Claim 3.
- A polysaccharide is required in Claim 2.
Design-around note: Using film formers that are neither polysaccharides nor within the listed mucoadhesive set may avoid dependent claims but not necessarily Claim 1 if Claim 1 does not require those specific polymers.
G. Dose levels
- Multiple numeric dose windows narrow embodiments.
Design-around note: Dose tailoring can avoid dependent numeric claims if the dependent claims are not literally met, without necessarily avoiding Claim 1.
What does this imply for the patent landscape around US 9,044,475?
1) Likely claim “center of gravity”
Within the set you provided, the center of gravity is the combination of:
- Sublingual apomorphine acid addition salt in film/strip format
- Two-layer structure
- Organic-base pH neutralizer layer
- Non-effervescent profile
- Permeation enhancer presence
This combination is a distinct product-by-process and product-by-structure package.
2) Most likely infringement hot spots
For a competing sublingual apomorphine film:
- If it uses apomorphine hydrochloride in the drug layer
- Has an organic base buffering layer under the same non-effervescent platform
- Employs a permeation enhancer (even if not glycerol monostearate)
- Uses a mucoadhesive polysaccharide film matrix
then it maps toward Claim 1 and several dependents.
3) Main design-around vectors
The highest-leverage “avoidance knobs” from the claims you provided are:
- Remove or change the permeation enhancer (or use a material that is not a “permeation enhancer” under claim construction).
- Change the pH neutralization system so the second layer does not contain an organic base as a pH-neutralizing agent.
- Change the dosage form architecture so it is not a film/strip or not organized into the claimed layer arrangement.
- Change salt identity away from hydrochloride to avoid dependent claims (while recognizing Claim 1 may still read if “acid addition salt” remains).
- Change effervescence behavior (gas generation systems likely create literal issues with “not effervescent”).
Where are the claim vulnerabilities and strength points?
Strength points
- Layered structural requirements create clearer infringement tests than purely functional claims.
- Material and excipient identity appears in multiple dependent claims (mucoadhesive polymer list; glycerol monostearate).
- Numeric dose and particle size windows narrow dependent coverage and support targeted enforcement.
Vulnerabilities (in-scope for analysis based on claim language provided)
- Claim 1 uses broad functional anchors (“permeation enhancer,” “pH neutralizing,” “acid addition salt”) that may invite disputes over whether a specific ingredient qualifies and whether a product behaves as claimed.
- Dependent claims create narrow “specific embodiment” coverage, which can reduce breadth for products that choose different polymers, different enhancers, or other dosing ranges.
Claim-by-claim checklist (operational)
| Claim |
What must be true (per your text) |
Scope effect |
| 1 |
Sublingual unit film/strip; 2 layers; layer 1 has apomorphine particles as an acid addition salt; layer 2 has pH-neutralizing organic base; not effervescent; includes permeation enhancer |
Broadest anchor; structural + functional gating |
| 2 |
Film/strip comprises a polysaccharide |
Narrows to polysaccharide-containing systems |
| 3 |
Mucoadhesive polymer is one from a defined list |
Narrow material set |
| 4 |
Acid addition salt = apomorphine hydrochloride |
Salt-specific narrowing |
| 5 |
Contains antioxidant |
Optional excipient; affects matching if omitted |
| 6 |
Permeation enhancer = glycerol monostearate |
Specific enhancer lock |
| 7 |
Particle size 1 to 10 µm |
Particle engineering limitation |
| 8 |
Salt = apomorphine hydrochloride |
Salt-specific narrowing in conjunction with claim 7 |
| 9 |
Dose 2 to 40 mg acid addition salt per unit |
Dose range narrowing |
| 10 |
Apomorphine particles in a mucoadhesive polymer |
Couples API particle to polymer architecture |
| 11 |
Optional third layer between first and second layers |
Allows multilayer variant |
| 12 |
Dose 12 to 30 mg |
Dose-range narrower |
| 13 |
Dose 12 ± 3 mg |
Specific embodiment |
| 14 |
Dose 22 ± 4 mg |
Specific embodiment |
| 15 |
Dose 30 ± 5 mg |
Specific embodiment |
| 16 |
Dose 35 ± 5 mg |
Specific embodiment |
Key Takeaways
- US 9,044,475 centers on a two-layer, non-effervescent sublingual apomorphine acid-addition-salt film/strip that pairs an organic-base pH-neutralizing layer with a permeation enhancer.
- Dependent claims narrow the landscape with specific mucoadhesive polymer exemplars, apomorphine hydrochloride, 1–10 µm particle size, glycerol monostearate, and tight mg-range embodiments (including several ± ranges).
- For product mapping, the most actionable “freedom-to-operate levers” in the claim text are: permeation enhancer selection, organic-base pH-neutralization requirement, film/strip layered architecture, and apomorphine salt form.
FAQs
1) Does Claim 1 require glycerol monostearate?
No. Claim 1 requires a permeation enhancer generally. Glycerol monostearate is specified in dependent Claim 6.
2) Can a product with three layers still infringe?
A product can align with the claim set if it has a third layer positioned between the first and second layers as covered by dependent Claim 11, while still meeting Claim 1’s layer 1 and layer 2 requirements.
3) Is apomorphine hydrochloride mandatory to fall under Claim 1?
Not on the face of Claim 1. Claim 1 requires an acid addition salt of apomorphine. Apomorphine hydrochloride is required in dependent claims such as Claims 4 and 8.
4) Is effervescence allowed in any embodiment?
The unit dosage form in Claim 1 is explicitly not effervescent. Dependent claims do not remove that constraint in the text you provided.
5) How do particle size limitations affect coverage?
Particle size 1 µm to 10 µm is required in dependent Claim 7 (and then also in the dependent salt-specific embodiment via Claim 8). A product outside that window may avoid those dependent claims, depending on how the claim hierarchy is applied.
References
[1] United States Patent 9,044,475. Claims as provided in the prompt text.
